Amitriptyline or Escitalopram: Four Dyspepsia Trial Checks

If a clinician suggests an antidepressant for upper abdominal symptoms, ask which symptom it targets and how you will judge whether it helps. Keep stomach symptoms, mood changes and side effects in separate parts of your appointment notes. These four checks explain why one trial needs a careful reading.

Who entered?

The Functional Dyspepsia Treatment Trial (FDTT) randomized 292 adults with Rome II functional dyspepsia, excluding depression, to amitriptyline, escitalopram or placebo for 12 weeks. Target doses were amitriptyline 50 mg/day and escitalopram 10 mg/day. Response required adequate relief in at least five of weeks 3–12.¹

Which comparison mattered?

Reported response was 53%, 38% and 40%, respectively. The three-group test gave P=0.05; amitriptyline versus placebo gave P=0.07, above the planned 0.025 threshold for two active-placebo comparisons. This does not establish amitriptyline’s overall superiority.¹

What remained uncertain?

The pain-predominant subgroup signal had an interaction P=0.06; it does not securely identify who benefits. Recruitment stopped at 292 of 400 planned. Gastric-emptying results did not establish a treatment mechanism. NIH funded the trial; Forest supplied escitalopram and matching placebo.¹

What belongs in care?

The British Society of Gastroenterology’s² 2022 guideline supports tricyclic antidepressants as second-line treatment for functional dyspepsia, with a strong recommendation and moderate-quality evidence. It does not support SSRIs for global dyspepsia symptoms. That broader evidence assessment should guide a discussion alongside this individual trial’s uncertainty. Ask which investigations and earlier treatments support the proposed next step.²

US amitriptyline labeling covers depression; dyspepsia use is off-label. Review heart-rhythm problems, constipation, urinary retention, glaucoma, sedating medicines and alcohol. Its boxed warning concerns increased suicidal thinking and behavior in children, adolescents and young adults; monitoring applies at every age. Promptly report suicidal thoughts or abrupt concerning mood changes. Discuss driving impairment and a prescriber-led stopping plan.³

Lexapro’s US indications are depression and generalized anxiety disorder, not dyspepsia. Its label also requires monitoring for suicidal thoughts and behavior, particularly early in treatment or with dose changes. Review MAO inhibitors, other serotonergic medicines, and bleeding risks with aspirin, anti-inflammatory medicines or anticoagulants. It recommends gradual dose reduction when stopping. Do not switch antidepressants or stop one abruptly based on this trial.⁴

Bloated by Dinner includes “The Visit Script”: bring your symptom record, describe the pattern, list medicines and supplements, and ask what has been ruled out and what comes next. Add a specific question about the proposed medicine: which change would count as worthwhile benefit, and when will we review it?